Rxivist logo

ISGylation drives basal breast tumour progression by promoting EGFR recycling and Akt signalling

By Alfonso Bolado-Carrancio, Morwenna Muir, Ailith Ewing, Kenneth Macleod, William Gallagher, Lan Nguyen, Neil Carragher, Colin Semple, Valerie G Brunton, Patrick Caswell, Alex von Kriegsheim

Posted 12 Sep 2019
bioRxiv DOI: 10.1101/767533

ISG15 is an ubiquitin-like modifier that is associated with reduced survival rates in breast cancer patients. However, the mechanism by which ISG15 achieves this remains elusive. We demonstrate that modification of Rab GDP-Dissociation Inhibitor Beta (GDI2) by ISG15 (ISGylation) alters endocytic recycling of the EGF receptor (EGFR). By regulating EGFR trafficking, ISGylation sustains Akt-signalling in vitro and in vivo. Persistent and enhanced Akt activation explains the more aggressive tumour behaviour observed in animal models and human breast cancers. We show that ISGylation can act as driver of tumour progression rather than merely being a marker of it.

Download data

  • Downloaded 219 times
  • Download rankings, all-time:
    • Site-wide: 66,287 out of 89,518
    • In cancer biology: 2,193 out of 3,154
  • Year to date:
    • Site-wide: 36,731 out of 89,518
  • Since beginning of last month:
    • Site-wide: 55,317 out of 89,518

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News